EUVIMEDEUVIMED entdecken
Crossref

Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor

Ryutaro Kanada iD, Yoshiko Kagoshima, Takashi Suzuki, Akifumi Nakamura, Hideaki Funami, Jun Watanabe, Masayoshi Asano, Mizuki Takahashi iD, Osamu Ubukata, Kanae Suzuki, Tomoya Aikawa, Kazumi Sato und 11 weitere

Journal of Medicinal Chemistry · 12.01.2023 · 66 (1) · 695-715

DOI: 10.1021/acs.jmedchem.2c01641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.12.2022. Verfasst von Ryutaro Kanada und 22 weiteren Autor:innen. Beteiligte Einrichtung: Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo140-8710, Japan. Hauptthemen laut MEDLINE: Histones, Histone Acetyltransferases. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistonesHistone AcetyltransferasesHumansMiceAnimalsAcetylationp300-CBP Transcription FactorsE1A-Associated p300 Protein

Substanzen

HistonesHistone Acetyltransferasesp300-CBP Transcription FactorsEP300 protein, humanE1A-Associated p300 Protein

Autor:innen und Institutionen

  • Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo140-8710, Japan.
  • Daiichi Sankyo RD Novare Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo134-8630, Japan.
  • Division of Genome Biology, National Cancer Center Research Institute, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo104-0045, Japan.
  • Division of Cancer Therapeutics, National Cancer Center Research Institute, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo104-0045, Japan.

ORCID-Profile: Ryutaro Kanada, Mizuki Takahashi

Zitieren

APA

Kanada, R., Kagoshima, Y., Suzuki, T., Nakamura, A., Funami, H., Watanabe, J., Asano, M., Takahashi, M., Ubukata, O., Suzuki, K., Aikawa, T., Sato, K., Goto, M., Setsu, G., Ito, K., Kihara, K., Kuroha, M., Kohno, T., Ogiwara, H., …, & Naito, H. (2023). Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor. Journal of Medicinal Chemistry, 66(1), 695-715. https://doi.org/10.1021/acs.jmedchem.2c01641

Vancouver

Kanada R, Kagoshima Y, Suzuki T, Nakamura A, Funami H, Watanabe J, et al. Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor. Journal of Medicinal Chemistry. 2023;66(1):695-715. doi:10.1021/acs.jmedchem.2c01641

BibTeX
@article{Kanada2023,
  author = {Kanada, Ryutaro and Kagoshima, Yoshiko and Suzuki, Takashi and Nakamura, Akifumi and Funami, Hideaki and Watanabe, Jun and Asano, Masayoshi and Takahashi, Mizuki and Ubukata, Osamu and Suzuki, Kanae and Aikawa, Tomoya and Sato, Kazumi and Goto, Megumi and Setsu, Genzui and Ito, Kentaro and Kihara, Kawori and Kuroha, Mutsumi and Kohno, Takashi and Ogiwara, Hideaki and Isoyama, Takeshi and Tominaga, Yuichi and Higuchi, Saito and Naito, Hiroyuki},
  title = {Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {1},
  pages = {695--715},
  doi = {10.1021/acs.jmedchem.2c01641}
}
Kostenlos starten →